Entering text into the input field will update the search result below

Xenon Pharma presents additional positive data from Phase 2b X-TOLE trial at AES 2021

Adult and child hands holding encephalography brain paper cutout, autism, Epilepsy awareness, seizure disorder, stroke, alzheimer, mental health concept

ThitareeSarmkasat/iStock via Getty Images

  • Xenon Pharmaceuticals (NASDAQ:XENE) announces that additional positive data from new sub-analyses of the Phase 2b X-TOLE clinical trial will be presented at the Annual Meeting of the American Epilepsy Society (AES 2021).
  • On October 4, 2021, the

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.